Zenas BioPharma

ZBIO

Market cap $1.97B

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation seeks to determine whether Zenas BioPharma's directors breached their fiduciary duties in connection with recent corporate actions.

- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -

WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management's presentations at the following investor conferences:

A pivotal clinical development has sent Zenas BioPharma NASDAQ: ZBIO shares climbing higher, reshaping the company's investment profile overnight. On Oct. 27, 2025, Zenas BioPharma's stock price climbed by over 30% on exceptionally high trading volume, pushing its market capitalization to approximately $1.35 billion and hitting a new 52-week high of over $34.

- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 -

The big banks have started off the new earnings-reporting season, which means that insider buying of stocks could be muted for a while.

Leon O. Moulder, the founder, Chief Executive Officer, and Chairman of the Board of Directors, acquired 36,928 shares of Zenas BioPharma (ZBIO -7.97%) on October 7, 2025, through an open-market purchase, as disclosed in the SEC Form 4 filing.

Zenas BioPharma (ZBIO) secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology indications. ZBIO's two late-stage candidates, obexelimab and orelabrutinib, drive optimism, with topline Phase 3 INDIGO trial data for obexelimab expected in late 2025. Strong cash position and recent private placement provide operational runway through 4Q26, supporting ongoing clinical development and mitigating dilution risks.

Zenas BioPharma said on Wednesday it has secured global rights to develop and commercialize an experimental drug from China-based InnoCare Pharma for multiple sclerosis and other autoimmune conditions under a licensing deal potentially worth more than $2 billion.

- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple Sclerosis (MS) -